2023-509969-20-00已完成1 期
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 127
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
GSM-CT
Scientific
Celgene Corp.
研究点 (4)
Loading locations...
相似试验
招募中
1 期
clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee2024-514833-39-00Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz60
已完成
1 期
A clinical trial in healthy people to look at how the body processes RO7268489 over time and when taken before or after a meal2023-503528-25-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG36
招募中
4 期
PROSPECTIVE RANDOMISED CLINICAL TRIAL TO EVALUATE THE EARLY RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER BETWEEN THE USE OF CHEMOHYPERTHERMIA (QH) WITH MITOMYCIN-C PRIOR TO TRANSURETHRAL BLADDER RESECTION IN A MAJOR OUTPATIENT SURGERY PROGRAMME AND TREATMENT WITH MITOMYCIN-C IN NORMOTHERMIA POST-RESECTION.2024-519890-21-00University Hospital Of Canary Islands152
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
招募中
1 期
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers2023-503892-83-00Vivet Therapeutics35